Article

Ocular implant gets fast-track designation

The FDA has granted fast-track designation to a silicone matrix ocular implant that helps prevent corneal transplant rejection.

Jersey City, NJ-The FDA has granted fast-track designation to a silicone matrix ocular (episcleral) implant (LX201, Lux Biosciences Inc.) that steadily releases therapeutic doses of cyclosporine A locally to the eye to prevent corneal transplant rejection.

The implant is being tested in a 1-year pivotal LUCIDA clinical trial program that comprises two controlled studies investigating its use in patients at elevated risk of immune-mediated rejection or graft loss after cornea transplantation. The device is implanted under the eyelid into the episcleral space in a minimally invasive procedure.

"With this fast-track designation, we can work [more rapidly] to provide a much-needed therapy to patients," said Ulrich Grau, PhD, president and chief executive officer of Lux Biosciences. "If successful, [the ocular implant] would become the first treatment available for the prevention of corneal transplant rejection."

The silicone matrix ocular implant has received orphan drug status in the United States and Europe.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
© 2025 MJH Life Sciences

All rights reserved.